back
Get SIGNAL/NOISE in your inbox daily
Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via an new AI platform. | Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform.
Recent Stories
Jan 19, 2026
Stop ignoring AI risks in finance, MPs tell BoE and FCA
Treasury committee urges regulators and Treasury to take more ‘proactive’ approach
Jan 19, 2026OpenAI CFO Friar: 2026 is year for ‘practical adoption’ of AI
OpenAI CFO Sarah Friar said the company is focused on "practical adoption" in 2026, especially in health, science, and enterprise.
Jan 19, 2026OpenAI’s 2026 ‘focus’ is ‘practical adoption’
As the company spends a huge amount of money on infrastructure, OpenAI is working to close the gap on what AI can do and how people actually use it.